Synergy Pharma (SGYP) Adds to Gains as Analyst Stokes Speculation Fire
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
BTIG Affirms 'Buy' Rating on Synergy Pharma (SGYP) Ahead of Pivotal Plecanatide Data in IBS-C
September 16, 2016 11:42 AM EDTBTIG affirms Synergy Pharma (Nasdaq: SGYP) at Buy with a price target of $11 ahead of the potential release of pivotal Phase 3 top line results in IBS-C, which is expected in Q416.
Analyst Timothy Chiang commented today, We believe visibility on plecanatide (the Co.s late... More
Synergy Pharma (SGYP) May be Potential Target for Takeda - Bloomberg, Citing Citi
September 14, 2016 9:36 AM EDTSynergy Pharma (NASDAQ: SGYP) May be Potential Target for Takeda - Bloomberg, Citing Citi
... More
